ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Scientist II at Vaxcyte - ApplyBlast

Scientist II

Vaxcyte

22 days ago

3.9 on Glassdoor

San Carlos, California, United States

Onsite

Full Time

Medior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Vaxcyte is seeking a Scientist II to join the Upstream Polysaccharide Process Development team, focusing on designing, executing, and optimizing microbial fermentation processes for polysaccharide manufacturing. The role involves hands-on laboratory work, technical troubleshooting, and collaboration with cross-functional teams to support vaccine production. The successful candidate will lead project activities, provide guidance to junior members, and communicate scientific results to stakeholders.

Responsibilities

Design and execute upstream polysaccharide fermentation studies for process development and optimization
Develop and troubleshoot fermentation processes to improve product yield, quality, and robustness
Lead project activities, provide technical guidance to junior members, and collaborate with cross-functional teams

Skills

Qualifications

PhD in Chemical Engineering, Biochemical Engineering, Biotechnology, Microbiology, or a related disciplineMS in Chemical Engineering, Biochemical Engineering, Biotechnology, Microbiology, or a related disciplineBS/BA in Chemical Engineering, Biochemical Engineering, Biotechnology, Microbiology, or a related discipline

About Vaxcyte

vaxcyte.com

Headquarters

San Carlos, California, United States

Company Size

51-200 employees

Founded

2013

View Profile

Vaxcyte is a clinical-stage vaccine innovation company dedicated to eliminating bacterial infections — including invasive pneumococcal disease, Group A Strep, and Shigella — using advanced chemistry and a proprietary cell-free protein synthesis platform. Its lead programs, VAX-31 (a 31-valent PCV) and VAX-24 (a 24-valent PCV), are being evaluated in Phase 3 trials for the prevention of invasive pneumococcal disease, with additional early-stage candidates targeting Group A Strep and Shigella. Vaxcyte is also investing up to $1 billion in U.S. biomanufacturing expansion to support scalable vaccine production.